Case Studies

Real-world evidence of delivering strategic insights to the pharmaceutical industry

Inpharmation runs global projects for the majority of top-50 pharmaceutical companies, across all major therapy areas.
Below you can browse a selection of projects showcasing examples of real-world strategic insights Inpharmation delivers.
To receive your full free copy of any case study:
  1. Click on the business scenario that most interests you.
  2. Submit a request via the download instructions.

Strategies to maximize revenue in a crowded market

A top-10 pharma company with an extensive ophthalmology portfolio was competing in crowded and competitive markets. Insight was required to understand if ophthalmology pricing could be improved. There was a requirement to optimise revenue for different product ranges in 4 countries, 3 therapy areas and across 4 stakeholder groups (including physicians, buyers, and patients).

Read More

IRP launch analysis report

A top-10 pharma company was launching a new medical device and wanted to understand the impact of international reference pricing on its product’s list price development. An IRP launch analysis report communicated a recommended launch strategy to optimize pricing prospects.

Read More

Market Simulator for MDD

A top ten pharma company with a number of pipeline assets required market research and market simulator development that could launch with a MDD and/or TRD indication. There was a requirement to model patient numbers and revenue across 7 major markets, for each line of therapy, considering specific comorbidity combinations.

Read More

Optimizing price for new competitor launches

A top-10 pharma company was launching a product within a new therapy class treating rheumatoid arthritis. The class represented a clinical improvement over current treatments on the market, so accurate value based pricing research was vital. The client wanted to know whether it could increase revenue by pricing lower to gain access to earlier lines […]

Read More

Strategies to determine pricing potential of an early asset

A client had an in-licensing opportunity for a product in development to treat osteoarthritis. The client required a early asset pricing analysis to look at the product’s pricing potential in order to determine whether the product would be an acceptable investment.

Read More

Multi-indication pricing case study

A pharma company had an add-on biologic to treat COPD, asthma and a number of further indications. The requirement was to analyze the product’s pricing potential. The product had already launched as an add-on for asthma. A recommended optimal pricing strategy was needed for both COPD and further indications. The customer wanted to see whether […]

Read More

Demand market research in a developing therapy area

A top-10 pharma company was launching a product in NASH, a therapy area with no established pharmacological treatments and with few established treatment pathways. Over the coming decade a large number of novel treatments were forecast to enter the market. The new product represented a clinical improvement over many of the new treatments predicted to […]

Read More

Tender pricing research and simulator

In anticipation of a loss of exclusivity event for their market-leading α-TNF biologic, a top-10 pharma company needed a recommendation for the optimal UK discounting strategy, in order to maximize revenue upon launch of the first biosimilar. A tender pricing research approach was recommended, as the purchase of biologics in the UK becomes tender-based upon […]

Read More

Behavior-Based Pricing for Rheumatoid Arthritis

A top-5 pharma company had an early-stage asset to treat rheumatoid arthritis (RA). Due to the early development stage of the asset, the final TPP was uncertain. The customer needed to understand the pricing potential for the asset across a range of TPP scenarios, for the EU5 and US.

Read More

Pricing Research for Multiple Payer Segments

Following on from a successful introduction in the EU, a new oncology brand was to be launched in Russia. This would start with one year of ‘free pricing’, prior to later potential national reimbursement (essential drugs list, or ‘EDL’ listing). During the ‘free pricing’ period, patients would only be able to access the therapy by […]

Read More

International Reference Pricing for an Atypical Antipsychotic

A top-50 pharma company had an asset to treat bipolar depression and wanted to understand the impact of international reference pricing on the product’s list price over the next 7 years. The vast majority of European countries, as well as many other countries across the world, conduct IRP to set the price of atypical antipsychotics. […]

Read More

Scroll Top